NASDAQ:BABY - Natus Medical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$27.32 +0.55 (+2.05 %)
(As of 02/19/2019 03:45 AM ET)
Previous Close$26.77
Today's Range$26.74 - $28.15
52-Week Range$25.06 - $37.95
Volume1.15 million shs
Average Volume552,397 shs
Market Capitalization$922.21 million
P/E Ratio19.24
Dividend YieldN/A
Beta0.58
Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders. The company provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. It offers diagnostic electroencephalography (EEG), ambulatory EEG, and long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, intra-operative monitoring, and diagnostic and monitoring transcranial doppler ultrasound technology systems. The company also provides hearing screening products to screen the hearing; diagnostic hearing assessment products to screen for or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems; balance and mobility systems to diagnose and assist in treating balance disorders; and thermoregulation products to control the incubators and warmers. In addition, it offers jaundice management products to treat jaundice; brain injury products to diagnose the severity of brain injury; NICVIEW, a live streaming video for families with babies in the neonatal intensive care unit (NICU); and essential products used in the everyday operation of NICU. Further, the company provides computer-based audiological, otoneurologic, and vestibular instrumentation and sound rooms to hearing and balance care professionals. It serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Natus Medical Incorporated was founded in 1987 and is headquartered in Pleasanton, California.

Receive BABY News and Ratings via Email

Sign-up to receive the latest news and ratings for BABY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:BABY
CUSIP63905010
Phone925-223-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$530.89 million
Cash Flow$2.9376 per share
Book Value$11.80 per share

Profitability

Net Income$-20,290,000.00

Miscellaneous

Employees1,726
Market Cap$922.21 million
OptionableOptionable

Natus Medical (NASDAQ:BABY) Frequently Asked Questions

What is Natus Medical's stock symbol?

Natus Medical trades on the NASDAQ under the ticker symbol "BABY."

How will Natus Medical's stock buyback program work?

Natus Medical announced that its Board of Directors has approved a stock repurchase program on Thursday, February 22nd 2018, which authorizes the company to buyback $30,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company's board believes its stock is undervalued.

How were Natus Medical's earnings last quarter?

Natus Medical Inc (NASDAQ:BABY) issued its earnings results on Wednesday, February, 13th. The medical equipment provider reported $0.43 EPS for the quarter, missing the consensus estimate of $0.50 by $0.07. The medical equipment provider earned $141 million during the quarter, compared to analyst estimates of $135.80 million. Natus Medical had a positive return on equity of 11.64% and a negative net margin of 4.32%. The business's revenue was up 7.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.42 earnings per share. View Natus Medical's Earnings History.

When is Natus Medical's next earnings date?

Natus Medical is scheduled to release their next quarterly earnings announcement on Wednesday, April 24th 2019. View Earnings Estimates for Natus Medical.

What guidance has Natus Medical issued on next quarter's earnings?

Natus Medical updated its FY19 earnings guidance on Wednesday, February, 13th. The company provided EPS guidance of $1.12-1.49 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.64. The company issued revenue guidance of $490-510 million, compared to the consensus revenue estimate of $528.15 million.Natus Medical also updated its FY 2019 guidance to $1.12-1.49 EPS.

What price target have analysts set for BABY?

2 analysts have issued 12 month price objectives for Natus Medical's stock. Their predictions range from $36.00 to $36.00. On average, they expect Natus Medical's stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 31.8% from the stock's current price. View Analyst Price Targets for Natus Medical.

What is the consensus analysts' recommendation for Natus Medical?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natus Medical in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Natus Medical.

Has Natus Medical been receiving favorable news coverage?

News articles about BABY stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Natus Medical earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave media stories about the medical equipment provider a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future.

Who are some of Natus Medical's key competitors?

Who are Natus Medical's key executives?

Natus Medical's management team includes the folowing people:
  • Mr. Jonathan A. Kennedy, Pres, CEO & Director (Age 48)
  • Dr. D. Christopher Chung, VP of Quality, Regulatory Affairs & Chief Medical Officer (Age 55)
  • Mr. Austin F. Noll III, Exec. VP & Chief Commercial Officer (Age 52)
  • Mr. Benjamin Drew Davies, Exec. VP & CFO (Age 53)
  • Mr. Seán Langan, VP Global Operations

Who are Natus Medical's major shareholders?

Natus Medical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.38%), Eagle Asset Management Inc. (5.00%), Dimensional Fund Advisors LP (4.73%), Vaughan Nelson Investment Management L.P. (2.96%), Nuveen Asset Management LLC (2.38%) and Confluence Investment Management LLC (2.37%). Company insiders that own Natus Medical stock include Dong Chune Christopher Chung, Doris Engibous, James B Hawkins, Jonathan Kennedy, Ken Ludlum, Robert A Gunst and William M Moore. View Institutional Ownership Trends for Natus Medical.

Which major investors are selling Natus Medical stock?

BABY stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Voce Capital Management LLC, Impax Asset Management Group plc, Diamond Hill Capital Management Inc., Confluence Investment Management LLC, Sapience Investments LLC, Nuveen Asset Management LLC and Barclays PLC. Company insiders that have sold Natus Medical company stock in the last year include Dong Chune Christopher Chung, James B Hawkins, Jonathan Kennedy, Ken Ludlum, Robert A Gunst and William M Moore. View Insider Buying and Selling for Natus Medical.

Which major investors are buying Natus Medical stock?

BABY stock was acquired by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P., BlackRock Inc., Rutabaga Capital Management LLC MA, Natixis Advisors L.P., Strs Ohio, Geode Capital Management LLC, WCM Investment Management LLC and Martingale Asset Management L P. View Insider Buying and Selling for Natus Medical.

How do I buy shares of Natus Medical?

Shares of BABY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Natus Medical's stock price today?

One share of BABY stock can currently be purchased for approximately $27.32.

How big of a company is Natus Medical?

Natus Medical has a market capitalization of $922.21 million and generates $530.89 million in revenue each year. The medical equipment provider earns $-20,290,000.00 in net income (profit) each year or $1.42 on an earnings per share basis. Natus Medical employs 1,726 workers across the globe.

What is Natus Medical's official website?

The official website for Natus Medical is http://www.natus.com.

How can I contact Natus Medical?

Natus Medical's mailing address is 6701 KOLL CENTER PARKWAY SUITE 120, PLEASANTON CA, 94566. The medical equipment provider can be reached via phone at 925-223-6700 or via email at [email protected]


MarketBeat Community Rating for Natus Medical (NASDAQ BABY)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  251 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  515
MarketBeat's community ratings are surveys of what our community members think about Natus Medical and other stocks. Vote "Outperform" if you believe BABY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BABY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel